Any Condition Underlying Critical IllnessSWIC-BNCT07582601
SWedish Intensive Care Biobank
An observational study of Any Condition Underlying Critical Illness, run by Uppsala University.
Trial summary
The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Any Condition Underlying Critical Illness
- How many people
- 25,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2027to 30 Dec 2035
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Any patient admitted to intensive care at a hospital in Sweden
Who may be able to join
- Adults admitted to intensive care in Sweden
Who cannot join
- Non adults
- Not admitted to intensive care
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Hereditary Influence on Risk Factors for Severe Illness in a Swedish Intensive Care Biobank
The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden. The main questions it aims to answer are:
Which genetic variants are associated with increased risk of critical illness from conditions such as infections, sepsis, and organ failure?
Read more
Can circulating proteins and metabolites mediate the effect of genetic risk factors on the severity of illness?
Participants will:
Provide blood samples at ICU admission and again 3-6 months after discharge Consent to genetic analysis and data linkage with national health registries
Have their ICU treatment and outcomes followed using registry and clinical data
This study aims to build a national infrastructure for rapid sample collection and analysis that can also support research in future pandemics.
- Keywords
- critical illness, shock, sepsis, heart failure, ards, acute kidney injury, infection, organ failure, intensive care
- Medical subject headings
- Critical Illness, Shock, Sepsis, Heart Failure, Acute Lung Injury, Acute Kidney Injury, Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ICU admission | Any patient admitted to ICU in Sweden |
What is being measured
The primary outcome is the main question the study is designed to answer.
30 day mortality
Death of any cause within 30 days of ICU admission
Measured: 30 days
ICU admission
ICU admission for any specific cause
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2026
- Study start1 Jan 2027 (estimated)
- Primary completion30 Dec 2035 (estimated)
- Study completion30 Dec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Any Condition Underlying Critical IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 25,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Uppsala University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael Hultström, Uppsala University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07582601
- Sponsor's protocol ID
- SWIC-B
- Other IDs
- 2024-04531-01
- Acronym
- SWIC-B
- Status last verified
- May 2026
- First submitted
- 24 Nov 2025
- Last updated
- 13 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Swedish legal requirements preclude sharing individual patient data. Patient data access for collaborators is provided on a secure system.
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hereditary Influence on Risk Factors for Severe Illness in a Swedish Intensive Care Biobank
- ClinicalTrials.gov ID
- NCT07582601
- Acronym / sponsor ID
- SWIC-B / SWIC-B
- Keywords
- critical illness, shock, sepsis, heart failure, ards, acute kidney injury, infection, organ failure
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 25,000 participants (estimated)
- Lead sponsor
- Uppsala UniversityUniversity, hospital or other
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 30 Dec 2035 (estimated)
- Study completion
- 30 Dec 2035 (estimated)
- First posted
- 13 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden. The main questions it aims to answer are:
Which genetic variants are associated with increased risk of critical illness from conditions such as infections, sepsis, and organ failure?
Can circulating proteins and metabolites mediate the effect of genetic risk factors on the severity of illness?
Participants will:
Provide blood samples at ICU admission and again 3-6 months after discharge Consent to genetic analysis and data linkage with national health registries
Have their ICU treatment and outcomes followed using registry and clinical data
This study aims to build a national infrastructure for rapid sample collection and analysis that can also support research in future pandemics.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ICU admission | – | –Any patient admitted to ICU in Sweden |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Any patient admitted to intensive care at a hospital in Sweden
Key inclusion criteria (1 listed)
- Adults admitted to intensive care in Sweden
Key exclusion criteria (2 listed)
- Non adults
- Not admitted to intensive care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
30 day mortality
Time frame: 30 days
Death of any cause within 30 days of ICU admission
ICU admission
Time frame: 30 days
ICU admission for any specific cause
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- Individual participant dataSharing planned: No. Swedish legal requirements preclude sharing individual patient data. Patient data access for collaborators is provided on a secure system.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Any Condition Underlying Critical Illness, run by Uppsala University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michael Marks-Hultström, MD PhD (0186110000, michael.hultstrom@mcb.uu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
30 day mortality (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.